Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma

Bone Marrow Transplant. 2024 Apr;59(4):569-571. doi: 10.1038/s41409-024-02205-6. Epub 2024 Jan 25.
No abstract available

Publication types

  • Letter

MeSH terms

  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Lymphoma, Large B-Cell, Diffuse* / therapy
  • Lymphoma, Non-Hodgkin*
  • Receptors, Antigen, T-Cell
  • Standard of Care


  • tisagenlecleucel
  • Receptors, Antigen, T-Cell